Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Tiziana Claudia Aranzulla Added: 5 months ago
ESC Congress 2025 - Evolocumab on top of lipid lowering therapy(LLT) reduced adverse vascular events at 12 months.Dr Tiziana Claudia Aranzulla (Mauriziano Umberto Hospital, Turin, IT) joins us to discuss findings from CARUSO (NCT04730973). The trial aimed to assess the efficacy of evolocumab with traditional LLT compared to traditional LTT alone in the stabilisation and regression of carotid… View more
Job title: Professor of Cardiology, Wu Family Endowed Chair of Cardiology, Consultant Interventional Cardiologist
Prof Ramzi Y. J. Khamis is the Wu Family Endowed Chair of Cardiology at Imperial College London and Consultant Interventional Cardiologist at Imperial College Healthcare NHS Trust, where he leads the High-Risk Atherosclerosis and Cardio-Immune Clinic. He previously served as Clinical Director of Cardiology and Cardiothoracic Surgery at the Trust.His clinical expertise lies in interventional… View more
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 1 year ago
What’s hot at ACC.24?Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.This preview episode of View from the Thoraxcenter offers a critical analysis of the most anticipated trials of ACC.24,… View more
Job title: President and Medical Director
Personal History Dr Renu Virmani was born in 1943 in Pakistan. Her father was an industrialist of Delhi and Amritsar, India.2 As the youngest girl in a family of ten children, Dr Virmani was always driven to stand out and excel. Her aunt, who was a neurologist, was instrumental in forging her ambitions to pursue medicine. “I admired her and she showed me that women can do whatever they want… View more
Added: 1 year ago
What’s hot at ACC.24?Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.This preview episode of View from the Thoraxcenter offers a critical analysis of the most anticipated trials of ACC.24,… View more
Research Area(s) / Expertise:

Coronary Interventions

Structural Intervention

Job title: Interventional Cardiologist
Dr Prasad Gunasekaran is an interventional cardiologist with a focus on transcatheter structural heart interventions from Mercy Heart Hospital, Springfield, MO. He holds a special interest in intracoronary imaging with IVUS/OCT and vulnerable coronary plaques. His clinical practice involves use of intracardiac echo (ICE) for structural heart interventions and low-contrast precision percutaneous… View more
Author(s): Matthew J Budoff Added: 10 months ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical… View more
Dr. Sangiorgi graduated at the University of Rome Tor Vergata in 1990. He is Board Certified in Cardiology (1994) and in Surgical Pathology (1999). He served as a Fellow in Cardiovascular Disease at the Mayo Clinic and Foundation, Rochester, USA from 1992 to 1999 and became Research Associate in Interventional Cardiology with Dr. Robert S. Schwartz and Dr. David Holmes Jr. He relocated to Milan… View more
Author(s): Alexander van Rosendael , Dipti Itchhaporia Added: 1 year ago
In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by Dr Alexander Van Rosendael (Leiden University Medical Center, Leiden, NL) to discuss the findings from the CONFIRM2 trial. Conducted from up to 50 international clinical CCTA sites with 35,000 patients, CONFIRM2 aims to improve comprehensive… View more